Denecimig Clears EMA Bar as Second FVIIIa Mimetic — HTA Comparator Gap Is the Real Test

CHMP Recommends EU Approval for Novo Nordisk's FREHEMGO®

Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for FREHEMGO® (denecimig). This FVIIIa mimetic bispecific antibody is intended for routine prophylaxis to prevent or reduce bleeding episodes in adults and children with haemophilia A, with or without inhibitors. FREHEMGO® is notable for being the first FVIIIa mimetic to offer flexible once-monthly, once-every-two-weeks, and once-weekly dosing options in a single-use pre-filled pen. The recommendation is supported by the FRONTIER trial program, which demonstrated significantly reduced annualised bleeding rates and a strong safety profile. Novo Nordisk anticipates launching FREHEMGO® in the first European countries in Q4 2026, with broader EU availability starting early 2027.

• The CHMP has recommended marketing authorisation for FREHEMGO® (denecimig) for the treatment of haemophilia A, including patients with or without inhibitors, across both adult and paediatric populations. This regulatory milestone positions FREHEMGO® as a significant advancement in the EU for managing congenital FVIII deficiency.
• FREHEMGO® is distinguished as the first FVIIIa mimetic to provide patients with flexible dosing regimens, offering once-monthly, once-every-two-weeks, and once-weekly prophylaxis. Its administration via a single-use pre-filled pen aims to reduce treatment burden and enhance patient convenience and freedom in managing their condition.
• The positive opinion is underpinned by the comprehensive FRONTIER trial program, including pivotal FRONTIER 2 and FRONTIER 3 studies. Denecimig consistently demonstrated significantly reduced annualised bleeding rates, often below 1, compared to prior treatments, with a substantial proportion of participants experiencing zero treated bleeds. The FRONTIER 5 trial also confirmed no new safety signals upon direct switching from emicizumab.
• Beyond the EU recommendation, Novo Nordisk submitted a Biologics License Application (BLA) for denecimig to the US Food and Drug Administration (FDA) in September 2025. This indicates the company's strategy for global market access and highlights ongoing regulatory reviews in other key regions for this novel haemophilia A treatment.

Addressing Key Challenges in Haemophilia A Prophylaxis

Despite meaningful advances in haemophilia A management, significant clinical, immunological, and logistical barriers continue to limit optimal outcomes across patient populations. These challenges span from the immunogenicity of replacement therapies to the practical constraints of prophylactic regimens and the evolving landscape of gene therapy.

• Inhibitor development against factor VIII (FVIII): Inhibitory antibodies to FVIII represent a major complication of replacement therapy. Risk is shaped by the underlying FVIII gene defect, with null F8 mutations associated with higher progression to high-titre inhibitors (odds ratio 2.6; 95% CI: 1.0–6.5), and by genetic determinants in the promoter regions of IL-10 and TNFα. Cohort data also link inhibitor formation risk to treatment intensity. Among children with newly diagnosed low-titre inhibitors, 50% progress to high titre, with family history of inhibitors (OR: 7.2; 95% CI: 1.8–28.4) and high-dose immune tolerance induction at ≥100 IU FVIII concentrate/kg/d (OR: 3.9; 95% CI: 1.5–10.0) identified as additional risk factors.

• Burden of immune tolerance induction (ITI): While ITI eliminates inhibitors in 60–80% of cases, it is costly and imposes significant economic and emotional burden on patients, families, and healthcare practitioners. For patients with persistent inhibitors or those who fail or are not candidates for ITI, bleeding-related mortality and morbidity increase and quality of life decreases compared with non-inhibitor patients.

• Treatment burden of prophylactic factor replacement: Conventional FVIII prophylaxis requires intravenous infusions two to four times per week, creating a high treatment burden and necessitating reliable venous access. The volume of clotting factor required also exceeds that of episodic treatment, compounding practical barriers — particularly in resource-limited settings such as South Africa, where fewer than 2,000 diagnosed haemophilia A patients are currently on prophylaxis despite it being the most prevalent clotting factor deficiency.

• Safety concerns with emicizumab in combination with aPCC: Emicizumab, the only globally approved non-factor therapy, carries a specific safety signal when used concurrently with activated prothrombin complex concentrate (aPCC). In HAVEN 1, three patients developed thrombotic microangiopathy (TMA) and two developed thrombosis when emicizumab was combined with aPCC at high or frequent doses. This raises ongoing concern about the safe management of breakthrough bleeding in patients on emicizumab prophylaxis.

• Gene therapy eligibility and durability limitations: AAV-based gene therapies for haemophilia A face eligibility restrictions due to pre-existing neutralising antibodies and immune responses to AAV capsids. Unlike haemophilia B, where factor IX expression remains more stable long-term, factor VIII levels in haemophilia A decline after peaking. Additional challenges include the difficulty of packaging the oversized FVIII transgene into AAV vectors, variable patient outcomes, and liver toxicity — manifesting as transaminase elevations — as the primary safety concern, typically managed with corticosteroids.

• Musculoskeletal sequelae from subclinical joint bleeding: Subclinical joint bleeding early in life contributes to measurable functional impairment. In a cohort of 273 children with haemophilia (mean age 9.8 years), orthopaedic assessments revealed clinically silent pressure pains in knee ligaments in 38% and in ankle ligaments and capsule in 60%, alongside significant deficits in fitness, endurance, coordination, and flexibility relative to healthy controls — underscoring the importance of early musculoskeletal assessment even in the absence of overt bleeding events.

FRONTIER Program: Denecimig's Efficacy and Safety Profile

Recent clinical evidence across haemophilia A spans gene therapy, bispecific antibody prophylaxis, extended half-life factor replacement, and recombinant factor concentrates, collectively illustrating the breadth of the current treatment landscape.

FREHEMGO's Differentiated Role in Haemophilia A Treatment

The treatment landscape for Haemophilia A has undergone substantial transformation, driven by the clinical validation of non-factor replacement therapies and long-acting factor concentrates. Emicizumab, a bispecific antibody substituting for activated FVIII, has demonstrated broad efficacy across patient subgroups. In the HAVEN 6 phase 3 study, emicizumab prophylaxis in people with non-severe haemophilia A without inhibitors produced an annualised bleed rate (ABR) of 0.9 (95% CI 0.55–1.52) for treated bleeds, with 67% of participants experiencing no treated bleeds over a median follow-up of 55.6 weeks. Real-world data from the ATHN 7 natural history study, encompassing 257 participants with a median emicizumab exposure of 116.4 weeks, reported a median ABR for treated bleeds of 0.25 (range 0–8.18) in participants with FVIII inhibitors and 0.51 (range 0–16.25) in those without, with no thromboses or thrombotic microangiopathy observed. UK registry data across 117 people with haemophilia A and inhibitors further confirmed a mean ABR of 0.32 (95% CI 0.18–0.39) over a median 42 months of emicizumab treatment, representing an 89% within-person reduction in ABR versus prior therapy.

Gene therapy has emerged as a paradigm-shifting modality, with valoctocogene roxaparvovec — an AAV5-mediated gene therapy — demonstrating durable haemostatic benefit over seven years in a phase 1/2 trial. In the 4 × 10¹³ vg/kg cohort, mean FVIII activity peaked at 21.1 IU/dL at week 52 before declining to 4.2 IU/dL by year 7, while mean ABR declined 87% from baseline to 1.6 bleeds/year and mean annualised FVIII use declined 93% to 10.3 infusions/year. Three of five participants in this cohort remained off prophylaxis at study end, and no serious treatment-related adverse events occurred after year 1. Indirect comparative analyses have also refined the positioning of newer factor concentrates: a matching-adjusted indirect comparison of efanesoctocog alfa versus emicizumab in adolescent and adult patients without inhibitors found that efanesoctocog alfa once-weekly was associated with significantly lower ABRs for any bleeds (incidence rate ratio 0.33 [95% CI 0.20–0.53]), any treated bleeds (0.49 [0.30–0.80]), and treated joint bleeds (0.51 [0.28–0.91]), alongside significantly greater improvement in Hemophilia Joint Health Score Total Score (mean difference −2.37 [95% CI −4.36; −0.39]) versus emicizumab.

Beyond pivotal trial data, real-world evidence has reinforced the clinical value of prophylactic strategies across resource settings. In Argentina, a multicentre retrospective cohort of 69 patients with haemophilia A and FVIII inhibitors showed that prophylactic treatment (incidence rate ratio 0.41, 95% CI 0.21–0.79, P < 0.01) and immune tolerance induction (IRR 0.47, 95% CI 0.27–0.81, P < 0.01) were each significantly associated with reduced ABR versus on-demand treatment. In resource-constrained settings, low-dose emicizumab prophylaxis at 1.5 mg/kg every 2 weeks produced a mean ABR of 0.41 ± 0.7, with 67% of patients achieving zero bleeds and 66% of target joints converting to non-target joints over a median 15-month follow-up. Collectively, these data reflect a treatment landscape increasingly defined by individualised, mechanism-diverse approaches — spanning non-factor replacement, gene therapy, and optimised factor concentrates — each supported by a growing body of both controlled and real-world evidence.

FREHEMGO®: A New Paradigm for Hemophilia A Prophylaxis

The European Medicines Agency's positive opinion for FREHEMGO® (denecimig) signals a pivotal moment for individuals living with haemophilia A. This recommendation paves the way for a novel FVIIIa mimetic bispecific antibody to enter the European market, offering a significant advancement in prophylactic treatment. What truly sets FREHEMGO® apart is its unprecedented dosing flexibility, providing options for once-weekly, once-every-two-weeks, or once-monthly subcutaneous administration. This level of choice, delivered via a convenient pre-filled pen, has the potential to profoundly impact patient adherence and quality of life, allowing treatment regimens to be tailored to individual lifestyles and clinical needs.

Clinical evidence from the comprehensive FRONTIER trial program underscores FREHEMGO®'s efficacy and safety. Studies indicate a substantial reduction in annualised bleeding rates, demonstrating superiority over both on-demand treatment and conventional clotting factor concentrate prophylaxis. Furthermore, the drug has consistently shown a favorable safety profile, being well tolerated with no reported thromboembolic events or neutralizing anti-Mim8 antibodies. While injection-site reactions were observed in a small percentage of patients or injections, they were generally mild. This robust data supports its use in a broad patient population, including those with or without factor VIII inhibitors.

Strategically, this approval positions FREHEMGO® as a formidable contender in the evolving haemophilia A market. Its 'next-generation' profile and flexible dosing could drive a shift in treatment paradigms, offering a compelling alternative to existing therapies. However, as with any new biologic, ongoing vigilance through post-marketing surveillance will be essential to monitor for any rare or long-term adverse events. The competitive landscape also demands clear differentiation and value communication to ensure optimal market penetration following its anticipated launch in late 2026 and early 2027.